Our findings indicate that the use of SGLT2 inhibitors among type 2 diabetes patients adhering to Ramadan practices did not yield a significant alteration in kidney function, as evidenced by eGFR levels. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.